Lilly's cancer drug Alimta has been turned down in the United Kingdom for treating a type of lung cancer, because it is not as cost-effective as competing drugs.
The U.K.'s National Institute for Health and Clinical Excellence said that evidence showed "no significant difference" in overall survival rates of patients who took Alimta compared to docetaxel, developed by Sanofi-Aventis, though Alimta is more expensive.
The panel said it would review Alimta again in 2010.
No comments:
Post a Comment